Slides
Page 1
NASDAQ: BHST The Botanical SynthesisCompanyInvestor PresentationSeptember 2025 NASDAQ: BHST
Page 2
NASDAQ: BHST Forward Looking StatementsThispresentationcontains"forward-lookingstatements."Thestatementscontainedinthispresentationthatarenotpurelyhistoricalareforward-lookingstatements.Forward-lookingstatementsgivetheCompany'scurrentexpectationsorforecastsoffutureevents.SuchstatementsaresubjecttorisksanduncertaintiesthatareoftendifficulttopredictandbeyondtheCompany'scontrolandcouldcausetheCompany'sresultstodiffermateriallyfromthosedescribed.Insomecases,forward-lookingstatementscanbeidentifiedbyterminologysuchas"may,""should,""potential,""continue,""expects,""anticipates,""intends,""plans,""believes,""estimates,"andsimilarexpressions.ThesestatementsincludestatementsregardingmovingforwardwithexecutingtheCompany'sglobalgrowthstrategy.Althoughthecompanybelievesithasidentifiedapathtoprofitabilitythereisnoassurancethatprofitabilitywillbeachievedasmanyfactorsbeyondthecontrolofthecompanycouldimpactitspotentialforprofitabilitysuchaschangesinconsumerpreferences,increasesincostsandchangesingovernmentregulation.Thestatementsarebaseduponcurrentbeliefs,expectationsandassumptionsandaresubjecttoanumberofrisksanduncertainties,manyofwhicharedifficulttopredict.TheCompanyisprovidingthisinformationasofthedateofthispresentationanddoesnotundertakeanyobligationtoupdateanyforward-lookingstatementscontainedinthispresentationasaresultofnewinformation,futureeventsorotherwise,exceptasrequiredbylaw.Wehavebasedtheseforward-lookingstatementslargelyonourcurrentexpectationsandprojectionsaboutfutureeventsandfinancialtrendsaffectingthefinancialconditionofourbusiness.Forward-lookingstatementsshouldnotbereadasaguaranteeoffutureperformanceorresultsandwillnotnecessarilybeaccurateindicationsofthetimesat,orby,whichsuchperformanceorresultswillbeachieved. 2
Page 3
NASDAQ: BHST BioHarvestIntroductionBioHarvestSciencesisabiotechinnovator&inventorofBotanicalSynthesis–theprocessofisolatingandmaximizingpotencyofphyto-nutrientsandmedicinalcompoundsplantcellsforcommercialapplicationswithoutgrowingtheplant Ilan Sobel Chief Executive Officer25+ years developing & executing strategic growth strategies Dr. Zaki RakibChairman of the Board30+ years experience developing disruptive technologies Dr. Yochi HagayChief Technology Officer20+ years experience in the pharmaceutical & biotech space Dr. Ilana BelzerChief Operating OfficerExtensive experience overseeing biotech companies Dr. Malkit AzachiVice President R&D20+ years experience developing biotechnologies Bar DichterChief Financial Officer Executive Leadership TeamCompany HighlightsOverview Consumer Products DivisionCDMO Division üPatented Botanical Synthesis Technology PlatformüSignificant demand for plant-derived, highly effective products across nutraceuticals, biotechnology/pharma and consumerüCommercial D2C products division with over $60m of lifetime revenueüScalable CDMO platform with numerous signed customers progressing through development 3 current customers, robust pipeline Pharma Company •5 product lines commercialized into 3 Multi-Billion $ Categories •65,000 Active Customers and #1 Resveratrol only Product on Amazon NASDAQ: BHST3
Page 4
NASDAQ: BHST Recent Developments –Q2 ResultsLatest Earnings HighlightsCDMO Services Division Updates Consumer Division Updates üSecured a new Stage 1 CDMO contract –developing plant-based fragrance compound from a plan under significant threat due to over-harvestingüAnnounced first CDMO project has reached Stage 2üCompletion of Stage 1 development for the CDMO contract with a Nasdaq-listed pharmaceutical companyüCDMO pipeline remains robust with multiple customers expected to convert in next 6-9 months üVINIA active users surpassed 65,000 since launch in May 2021üLaunched VINIA DailyChews 2X formula üAnnounced launch into functional hydration and sports drink category and “Health Pros” affiliate program •Q2 revenue growth of 41% vs. prior year to $8.52M•Q2 Adj EBITDA gross margin improvement of 600 bps•Q2 gross profit margin expanded 800bps to 60% $6.0$8.5 RevenueQ2'2024Q2'2025 52% -21% 60% -15%Gross Profit Margin %Adj. EBITDA Margin %3 Major Initiatives for 2H 2025 1.Entering hydration and sports drink category with “Blood Flow Hydration” Solution in October 20252.Launching VINIA “Health Pros” Professional Affiliate Program in Spetember–aiming for 300 pros by end of the year3.Launched AI enabled “Discovery Phase” giving clients access to discover the next generation plant biologics NASDAQ: BHST4
Page 5
NASDAQ: BHST Vision NORTH STAR OF BHSTIS TO DISCOVER,DEVELOP, MANUFACTURE& DEMOCRATIZE LIFE-CHANGING COMPOUNDS FROM PLANTSTHAT CHANGE THE WORLD OF HEALTH & WELLNESS FOR HUNDREDS OF MILLIONS OF PEOPLE WHILE PRESERVING THE PLANET FOR GENERATIONS TO COME PHARMA/BIOTECH NUTRITION /SWEETENERS NUTRACEUTICALS COSMETICS PROPRIETARYPLANT BASEDMOLECULES NATURAL SUSTAINABLE SUSTAINABLE CONSISTENT ECONOMICAL BHST is Addressing Unmet Health & Wellness Needs With Patentable Plant CompoundsProduced Consistently & Economically With the Highest Levels of Sustainability 5
Page 6
NASDAQ: BHST BioHarvestInvestment Highlights Proprietary Discovery Phase to Drive Future GrowthClose partnership to develop new life-changing compounds and products –driving profitable enterprise relationships with large opportunities Mature Technology with Significant Manufacturing Operations Set UpOne state-of-the-art biological production facilities with 25 metric tons of capacity and an additional 100 Ton facility to be built by end 2026 Attractive Operating Model for CDMO and Consumer DivisionsCDMO business generating NRE revenue today with line of sight to meaningful royalty streamsBusiness expects Adj.EBITDAbreakeven by end of 2025 Breakthrough Technology Disrupting a Stagnant Market Botanical Synthesis is a breakthrough technology providing high-quality, potent, and reliable plant-based life-changing compounds to commercial markets Expansive CDMO Opportunity CDMO division represents expansive opportunities to bring potent, plant-based molecules to mass commercial opportunities3 commercial deals signed + robust pipeline Proven Solution with D2CH & W Products DivisionOver $60m of products revenue in past 4 years, validates Botanical Synthesis process and market need 4 1 5 2 6 3 NASDAQ: BHST6
Page 7
NASDAQ: BHST We only require the plant once to mirror, magnifyand multiplyplant cells with unique phytomedicinal compounds. Global Leader in Plant Cell Biology with 15+ Years of Development and ~$100M Invested in the Platform14 Granted Patents –Multiple Pending Proprietary Technology Process Which Enables Development of Compounds for Next-Gen Therapeutic Solutions PERFORMEDONCE THEPLANT CELLISOLATION, MIRRORING&POTENCY MAGNIFICATION CELLBANK CELL BANK FINAL COMPOUNDDRYINGUPSTREAM DOWNSTREAM SMALL SCALEPROPAGATION PERPETUALPROCESS LARGE SCALE MULTIPLICATIONIN MID-SCALE BIOREACTORS 7
Page 8
NASDAQ: BHST Cleanliness /PurityEnvironmental SustainabilityEconomic Viability Inherently clean process due to aseptic growth conditions.Botanical synthesis uses much less resources, including land, water and electricity. In addition, growing a plant cell only requires a ‘real’ plant one time for future replication. Cells are grown directly in bioreactors and harvested every 3 weeks which creates up to 17 harvest cycles per year. The result is an order of magnitude lower cost of production. Turning Plants Into a Scientifically Reliable Source of Patentable Biological CompoundsBotanical Synthesis Offers Significant Advantagesin Production of Simple and Complex Compounds ConsistencyPatentabilityOptimal BioavailabilityProduction inherently has a degree of control not possible in nature.Botanical compositions patentable given concentrations not possible in nature.Maintaining the metabolites original molecular conformation while enabling the elicitation of certain important compounds. Molecular structure of the plant compounds are not changed in any way. Non-GMO NASDAQ: BHST8
Page 9
NASDAQ: BHST CDMO SERVICES BUSINESS UNIT APPLYING BOTANICAL SYNTHESIS AS A CDMO TO DEVELOP PLANT-BASED COMPOUNDS FOR:•MULTIPLE VERTICALS•3 DEALS SIGNED + ROBUST PIPELINE D2C WELLNESS BUSINESS UNIT •CDMO PROOF OF CONCEPT / MARKET VALIDATION•EFFICIENTLY MANUFACTURING AT SCALE •CASH GENERATOR BHST has 2 Growth Engines Powered by Our Botanical Synthesis Process Anchored by Dec. 2024 Deal with Tate & Lyle NASDAQ: BHST9
Page 10
NASDAQ: BHST Introducing VINIA®: Our Flagship Red GrapeCell-Derived Direct-to-Consumer Nutraceutical Product •*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease •VINIA®is BioHarvest’s first commercial product, a proprietary nutraceutical containing the entire matrix of red grape polyphenols, including Piceid Resveratrol•Proof of concept and market acceptance with over $50M in lifetime sales and over 50,000 active subscribers, validating the demand for products created using inherent advantages of Botanical Synthesis•Growing customer satisfaction (4.7/5average rating and 9,930+verified online reviews) coupled with positive feedback from healthcare professionals•Botanical Synthesis process increases Piceid Resveratrol concentration by at least 100x versus regular grapes (a principal health-benefitting compound in red grapes) •Breakthrough red grape cell powder that significantly increases artery dilation and blood flow, enhancing delivery of oxygen to cells& removal of toxins from the body•VINIA®is patent-protected with 3 peer-reviewed studies and 8 scientific studies•Available in the U.S., expanding into the Canadian market on recent regulatory approval, with additional regulatory efforts underway in Japanand Europe Providing Better Blood Flow for a Better Life: NASDAQ: BHST10
Page 11
NASDAQ: BHST Products Anchored in Science & Backed by Clinical Trials •*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Clinical trial published in peer reviewed scientific journalsbioharvest.com/clinical-studies NASDAQ: BHST11
Page 12
NASDAQ: BHST Our Disruptive Category Playbook Accesses Major Billion $ Categories USA HEART HEALTH, ENERGY HEALTH & MENTAL ALERTNESS MARKET –$13 BNUSA HYDRATION MARKET –$16 BILLION Q4 –25 (6 FLAVORS)MAY-21 Q4 -25JUNE -25 DEC-23 Q4-25 JUNE-25 (2 FLAVORS)DEC-24 USA FUNCTIONAL COFFEE AND TEA MARKET –$5 BN -"Functional Coffee -Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 –2029, "Functional Coffee -Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 -2029"”DATA HORIZON RESEARCH –FUNCTIONAL TEA MARKET 2 RESEARCH 2024PRECEDENCE RESEARCH -Electrolyte Drinks Market (By Type: Isotonic, Hypotonic, Hypertonic; By Packaging: PET Bottles, Cartons, Beverage Cans, Tetra pack, Pouches & Sachets; By Distribution Channels: Online, Offline) -Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032, STATISTA DEC 2022 –SKIN CARE & BEAUTY MARKET ESTIMATES NASDAQ: BHST12
Page 13
NASDAQ: BHST Repeating the VINIA Playbook: Olive & Pomegranate Cells •1) https://www.sciencedirect.com/science/article/abs/pii/S0944711323003884•2) https://www.sciencedirect.com/science/article/abs/pii/S1756464617304334 Business Model Can be Easily Replicated Across New Plant CompoundsExpectation to Begin Selling Olive Compound to Consumers in 2026 •Olives: Providing at least15X concentrated amounts of Verbascosideconcentration vs. a regular olive: a compound with antioxidant, anti-inflammatory and antineoplastic properties .1•Focus on Liver Health, Cholesterol & Joint Health –2026 Launch•In-vitro trials complete, which indicate the olive cells could protect against a cause of non-alcoholic fatty liver disease•Pomegranates: Providing at least10X concentrated amounts of PGG Polyphenol: a compound with anti-microbial, anti-diabetic, anti-inflammatory and anti-tumor properties2..•Focus on Brain Health Addressing Consumer Needs Through New Compounds •Olives and Pomegranate Cell powders can be expanded across Hot Beverages, Chews, Hydration Powders, Skincare and moreMirroring the VINIA Playbook •Further integrate consumers into the BioHarvest ecosystem, cross-selling incremental products to a loyal, captive audienceSell Through Opportunities NASDAQ: BHST13
Page 14
NASDAQ: BHST CDMO SERVICES BUSINESS UNIT APPLYING BOTANICAL SYNTHESIS AS A CDMO TO DEVELOP PLANT-BASED COMPOUNDS FOR:•MULTIPLE VERTICALS•3 DEALS SIGNED + ROBUST PIPELINE D2C WELLNESSBUSINESS UNIT BHST has 2 Growth Engines Powered by Our Botanical Synthesis Process •CDMO PROOF OF CONCEPT / MARKET VALIDATION•EFFICIENTLY MANUFACTURING AT SCALE •CASH GENERATOR Anchored by Dec. 2024 Deal with Tate & Lyle NASDAQ: BHST14
Page 15
NASDAQ: BHST CDMO Engines For Growth Significant Applications throughout the food and beverage market driven by sub optimal solutions today (i.e.Stevia) Nutrition & Sweeteners NutraceuticalsPharma & Biotech Cosmetics & Fragrances Major Health and Wellness focus driven by preventative medicine and move away from RX world of side effects Pharma: (a) Over 140 existing Rx small compounds utilize plant-based API, KSM, or excipients(b) pursuit of new compounds in clinical Ph1+Biotech: Over 100 biologics including vaccines, adjuvants, antibodies, and proteins that originate from plants Top players targeting 100% naturally derived ingredients by 2030, driven by major pressure from consumers DEVELOPMENT OF COMPOUNDSTO DRIVE DIFFERENTIATION IN MAJOR COMPETITIVE PROFIT POOLS (BEETS, ASHWAGANDA )10% OF FOCUS> $700 KG SUPER HIGH MARGIN COMPOUNDREPLACEMENT & NEW COMPOUNDDEVELOPMENT65% OF FOCUS>$5,000 KG DEVELOPMENT OF SUPER HIGH VOLUME/LOWERMARGIN COMPOUNDSTHAT WILL CHANGE THE FOOD CHAIN & FORCE BHSTTO BECOME THE LOWEST COST PRODUCER OF COMPOUNDS10% OF FOCUS>$500 KG Higher Margin | Lower VolumeLower Margin | Higher Volume DEVELOPMENT OF NEW HIGH MARGIN COMPOUNDSTHAT WILL DRIVE INDUSTRY DIFFERENTIATION FOR 2-3 GLOBAL PLAYERS15% OF FOCUS>$2,000 PER KG Anchored by Dec. 2024 Deal with Tate & Lyle Pharma Company-Listed NASDAQ: BHST15
Page 16
NASDAQ: BHST THECDMO SERVICES OFFERING DISCOVERY DEVELOPMENT ROYALTY BASED MANUFACTURINGPARTNERSHIPSupports molecule identification, development, and scale-upBioHarvestretains production rights with royalty-based modelApplicable across 4 major industries TAPPING INTOBILLION $BUSINESSOPPORTUNITIES THE BOTANICAL SYNTHESIS COMPANY NASDAQ: BHST16
Page 17
NASDAQ: BHST Stage 2 CORRECTOR & SAMPLER 6 –9 MONTHS Stage 1 PREDICTOR & SELECTOR 6 -9 MONTHS Stage 3 LARGE SCALE & PRODUCER 6 –9 MONTHS MANUFACTURING INDUSTRIAL &COMMERCIAL CONTINUOUS A PATENTABLE MASS-PRODUCIBLE BOTANICAL COMPOSITION DEVELOPMENT IS COMPLETED STAGED GATE DEVELOPMENT APPROACH TO ENSURE SUCCESS THE BOTANICAL SYNTHESIS COMPANY $2.5-3M BETWEEN 18-27 MONTHS ROYALTY BASED NEWDISCOVERY Stage SHORT LIST OF PLANT COMPOUNDS FOR CUSTOMER1 MONTH 17
Page 18
NASDAQ: BHST INDICATION-BASED INITIAL SCREENINGAI identifies plant candidates based on:Scientific evidence (MOA, trials, patents)Unique value proposition (efficacy, rarity, enhancement potential)Prior success in tissue cultureMOA & TISSUE CULTURE FILTERINGNarrowed to smaller number of plants with activity in ≥2 biological pathwaysCompatibility with tissue culture platform confirmedFEASIBILITY & PRODUCT ANALYSISEvaluation of:Active ingredients & formulationPatentability & regulationSourcing & safetyAI-driven process optimization (monitoring, CV, algorithms)FINAL SHORTLIST: 4–5 PLANTSMulti-pathway efficacy & full scalability within BioHarvestsystem DISCOVERY PHASEBIOHARVEST AI WORKFLOW Proprietary AI trained on rare plant biology & biosynthesisExpertise in botanical patenting & global regulationsProven full-scale production from indication to marketCORE STRENGTHS NASDAQ: BHST18
Page 19
NASDAQ: BHST Stage 2 CORRECTOR & SAMPLER 6 –9 MONTHS Stage 1 PREDICTOR & SELECTOR 6 -9 MONTHS Stage 3 LARGE SCALE & PRODUCER 6 –9 MONTHS MANUFACTURING INDUSTRIAL &COMMERCIAL CONTINUOUS A PATENTABLE MASS-PRODUCIBLE BOTANICAL COMPOSITION DEVELOPMENT IS COMPLETED STAGED GATE DEVELOPMENT APPROACH TO ENSURE SUCCESS THE BOTANICAL SYNTHESIS COMPANY $2.5-3M BETWEEN 18-27 MONTHS ROYALTY BASED NEWDISCOVERY Stage SHORT LIST OF PLANT COMPOUNDS FOR CUSTOMER1 MONTH 19
Page 20
NASDAQ: BHST BIOHARVESTCDMO PIPELINE HASMULTIPLE FUTURE CATALYSTS CATEGORYPRELIMINARY STAGE PROJECTSüLeading European pharma company specializing in respiratory and rare diseasesüMajor Chinese industry association representing pharma and health product stakeholdersüGlobal consumer health leader with a wide OTC and wellness portfolioüRegional pharma/nutramanufacturer with expertise in botanical formulations üBiotech innovator using microbial fermentation to produce high-value actives for heal üA leading global brewing company focused on leveraging advanced plant trait development to improve barley and other key brewing ingredientsüA proprietary extracellular delivery system containing naturally occurring biomolecules that modulate physiological responsesüGlobal OTC-focused health company driving innovation in self-care COSMECEUTICALüA leading direct-to-consumer beauty-tech company to co-develop novel bioactive ingredients for next-generation skincare applications üLeading European pharma company specializing in respiratory and rare diseasesüMajor Chinese industry association representing pharma and health product stakeholdersüGlobal consumer health leader with a wide OTC and wellness portfolioüRegional pharma/nutramanufacturer with expertise in botanical formulationsüA dermatology-focused biotech using a proprietary platform for treating infectious and inflammatory skin diseases üBiotech innovator using microbial fermentation to produce high-value actives for healthüA leading global brewing company focused on leveraging advanced plant trait development to improve barley and other key brewing ingredients üGlobal OTC-focused health company driving innovation in self-careüBiotech innovator using microbial fermentation to produce high-value actives for health üA leading direct-to-consumer beauty-tech company to co-develop novel bioactive ingredients for next-generation skincare applications FOOD NUTRACEUTICAL & WELLNESS 5 1 2 1 PHARMA & HEALTH NASDAQ: BHST20
Page 21
NASDAQ: BHST CDMO DEVELOPMENT REVENUE MODEL & ROYALTY POTENTIALTHE BOTANICAL SYNTHESIS COMPANY MANUFACTURING INITIATION TIMELINE AFTER DEVELOPMENT COMPLETION:Nutrition: Right after Stage 3Cosmetics: +6 monthsNutraceuticals: +1 yearPharma: +2 years (low scale),+4 years (high scale) 10 projects 6 projects 5 projects 4 projects Royalty based revenue STAGE 1 STAGE 2 STAGE 3 $5M $6M $5M THE AVERAGE DEVELOPMENT REVENUE PER PROJECT IS $1.6M Customer TypeTons Per YearPrice per TonRoyalty Revenue / TonPharma5>$5M$4M/TonCosmeceuticals30>$1.5M$1.2M/TonNutraceuticals100$600-800k$400k/TonNutrition500<$500k$300k/Ton ILLUSTRATIVE CDMO ROYALTY REVENUE PER TON PRODUCED 21
Page 22
NASDAQ: BHST In-House Biotech Manufacturing and R&D Facilities•Production and Corporate facility located in Yavneh, Israel•R&D offices located in Rehovot, Israel World Class Biological Production and R&D Team in Israel Yavne Facility #2Yavneh Facility #125 metric ton per year production capacity (est. $100M of product/annum)•Optimized for industrial production with a Botanical Synthesis•Produces unique plant compounds using a fraction of the time, space, electricity, water and manpower required for conventional agriculture 80,000 sqftPropertyIncludes 12 clean rooms, and space for 100 metric ton production facility•Includes all R&D functions•Allows CDMO customers to experience complete end-to-end development and manufacturing service Future Target: Planning to construct a 200 metric ton manufacturing facility in the United States to be completed by end of 2029 22
Page 23
NASDAQ: BHST Financial HighlightsQuarterly Revenue*$ in Millions *As of 6/31/2025 (USD $ in Millions)June 302025June 302024June 302023June 302022Revenue$8.5$6.0$2.8$0.8Gross Profit Margin59.7%51.5%32.6%N/A •Success of VINIA®Red Grape Cell product line drove Q2 2025 revenues to a record of $8.5 million, reflecting a year-over-year increase of 41%•Margin enhancement initiatives increased gross margins in Q2 2025 to 59.7% vs. 51.5% in the same year-ago quarter and 32.6% two years ago•Significant Operating Leverage with G&A as a % decreasing significantly •Investing for Growth& Profitability: Investing heavily to scale VINIA®sales, incremental new products and definedpath to adj. EBITDA breakeven in Q4 2025•CDMO Optionality: Long-term royalty potential through CDMO services business unit $2.8 $3.2 $4.5 $5.3 $6.0 $6.5 $7.3 $7.9 $8.5 Q22023Q32023Q42023Q12024Q22024Q32024Q42024Q12025Q22025 NASDAQ: BHST23
Page 24
NASDAQ: BHST Contact UsInvestor RelationsLucas A. ZimmermanMZ North AmericaMain: (949) 259-4987BHST@mzgroup.us BioHarvest Sciences (NASDAQ: BHST)625 Howe Street Suite 1140 Vancouver, BC V6C 2T6 Canadawww.bioharvest.com NASDAQ: BHST24